Author Guidelines
These guidelines describe the scientific, ethical and technical requirements for submitting to International Journal of Farmacia. Authors should read this page together with the relevant article-type, ethics and reporting guidance.
Submissions are accepted through OJS onlyBefore you submit
- Confirm that the work has a clear connection to pharmacy, pharmaceutical science or the responsible use of medicines.
- Choose the most appropriate article type and follow the applicable reporting guideline.
- Obtain approval from every listed author and from the responsible ethics body where the study requires it.
- Ensure the work is original, is not under consideration elsewhere and does not duplicate a previous publication.
- Prepare the manuscript, tables, figures, supplementary files and complete declarations before starting the online submission.
How to submit
- Create or use your OJS account. Sign in and begin a new submission using the journal's online workflow.
- Enter complete metadata. Supply the title, abstract, keywords, author names, affiliations, email addresses, ORCID iDs where available, funding and references accurately.
- Upload files. Upload the editable manuscript as the main file and add tables, figures, reporting checklists, ethics documentation or supplementary material as applicable.
- Provide declarations. Include authorship contributions, conflicts of interest, funding, ethics, consent and data-availability statements.
- Review and submit. Check the submission record carefully. The corresponding author is responsible for its completeness and for subsequent communication.
Do not submit the manuscript by ordinary email
Email may be used for a presubmission enquiry or technical assistance, but a manuscript enters editorial assessment only after a complete OJS submission has been created. Never send a publication payment before formal acceptance.
Language and presentation
Manuscripts must be written in clear scientific English. Either British or American spelling may be used consistently. Define non-standard abbreviations at first use; use SI units and internationally recognised non-proprietary drug names. Generic names should normally precede brand names, and a trade name should be included only when scientifically necessary.
File preparation
| File | Requirement |
|---|---|
| Main manuscript | Editable DOC or DOCX file, with continuous page numbers and line numbering where possible. |
| Tables | Editable tables, cited in numerical order, with concise titles and explanatory footnotes. |
| Figures | Clear, original figures cited in order; legends should explain symbols, groups and abbreviations without relying on the main text. |
| Supplementary material | Labelled files that are essential to transparency but not required in the main article. |
| Reporting checklist | Upload the appropriate checklist or flow diagram for the study design when one exists. |
References
IJF uses a numbered Vancouver style. Cite sources in the order of first appearance using Arabic numbers in square brackets. References in tables or figure legends follow the sequence established in the text. Authors are responsible for the accuracy, completeness and retrievability of every reference, including DOI or stable URL information where available. Retracted work should not be cited as valid evidence.
Research reporting
Use the relevant EQUATOR Network guideline: CONSORT for randomised trials, STROBE for observational studies, PRISMA for systematic reviews, CARE for case reports, STARD for diagnostic-accuracy studies, ARRIVE for animal research and other design-specific standards. Guideline use does not replace scientific judgment; it helps readers assess what was done and found.
After submission
The editorial office may return incomplete or out-of-scope submissions before peer review. Revisions must respond to every editorial and reviewer point in a numbered response document and identify corresponding changes in the manuscript. After acceptance, authors must check proofs promptly for production errors; proof correction is not an opportunity for unapproved changes to the study or authorship.
